.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on INSUMAN RAPID (insulin human): temporary supply shortage and marketing cessation - Direct communication with healthcare professionals on INSUMAN RAPID (insulin human): temporary supply shortage and marketing cessation
Direct communication with healthcare professionals on INSUMAN RAPID (insulin human): temporary supply shortage and marketing cessation
Issues at a manufacturing site in the past months resulted in a temporary critical global supply situation affecting the product Insuman Rapid.
In Italy the shortage is expected to begin on:
- - 31/01/2023 for INSUMAN RAPID A.I.C. n. 038923431
- - 23/01/2023 for INSUMAN RAPID A.I.C. n. 034185850
The expected date to return to normal supply is December 2023.
No new patients should be initiated with any of the impacted INSUMAN RAPID presentations and existing patients should be switched to suitable alternatives. Interruption of insulin treatment is potentially life threatening.
Therefore, replacement with alternative insulin formulations is needed to avoid hyperglycaemia and serious complications.
Published on: 16 January 2023
🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m...
Vai al post →
💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ...
Vai al post →
⚠️ Attenzione alle false cure miracolose
Negli ultimi tempi si sta diffondendo un business pericol...
Vai al post →
#AIFA promuove l’ascolto e la trasparenza
Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr...
Vai al post →
Oggi si celebra il #WorldAutismAwarenessDay.
🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →
